Smoking cessation: Lessons learned from clinical trial evidence

Current Opinion in Cardiology

Volumn 22, Issue 4, 2007, Pages 280-285

  Reid, Robert D ^a   Quinlan, Bonnie ^a   Riley, Dana L ^a   Pipe, Andrew L ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Counseling; Intervention; Medications; Nicotine dependence; Smoking cessation

Indexed keywords

AMFEBUTAMONE; RIMONABANT; VARENICLINE;

CANADA; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; EUROPE; EVALUATION; EVIDENCE BASED MEDICINE; FOLLOW UP; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; REVIEW; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; UNITED STATES;

BENZAZEPINES; BUPROPION; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DOPAMINE UPTAKE INHIBITORS; HUMANS; NICOTINIC AGONISTS; PIPERIDINES; PYRAZOLES; QUINOXALINES; SMOKING; SMOKING CESSATION;

EID: 34250168680     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328236740a     Document Type: Review

References (53)

1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 2001; 104:2855-2864.
2. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001; 104:2746-2753.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349:1498-1504.
4. US Department of Health and Human Services. The health consequences of smoking: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2004.
5. Teo KK, Ounpuu S, Hawken S, et al. Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet 2006; 368:647-658.
6. US Department of Health and Human Services. The health consequences of involuntary exposure to tobacco smoke: a report of the Surgeon General. Rockville: US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006. A comprehensive review (727 pages) of the evidence concerning the adverse health effects from exposure to tobacco smoke, including effects on CHD.
7. Raupach T, Schafer K, Konstantinides S, et al. Secondhand smoke as an acute threat for the cardiovascular system: a change in paradigm. Eur Heart J 2006; 27:386-392.
8. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997; 29:1422-1431.
9. Smith CJ, Fischer TH. Particulate and vapor phase constituents of cigarette mainstream smoke and risk of myocardial infarction. Atherosclerosis 2001; 158:257-267.
10. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 2004; 43:1731-1737.
11. Frohlich M, Sund M, Lowel H, et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J 2003; 24:1365-1372.
12. Rea TD, Heckbert SR, Kaplan RC, et al. Smoking status and risk for recurrent coronary events after myocardial infarction. Ann Intern Med 2002; 137:494-500.
13. Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: results from the Third National Health and Nutrition Examination Survey. PLoS Med 2005; 2:e160.
14. Barone-Adesi F, Vizzini L, Merletti F, et al. Short-term effects of Italian smoking regulation on rates of hospital admission for acute myocardial infarction. Eur Heart J 2006; 27:2468-2472.
15. Bartecchi C, Alsever RN, Nevin-Woods C, et al. Reduction in the incidence of acute myocardial infarction associated with a citywide smoking ordinance. Circulation 2006; 114:1490-1496. The first confirmatory study showing that a public ordinance reducing exposure to secondhand smoke was associated with a decrease in hospitalizations for acute myocardial infarction.
16. Sargent RP, Shepard RM, Glantz SA. Reduced incidence of admissions for myocardial infarction associated with public smoking ban: before and after study. BMJ 2004; 328:977-980.
17. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004; 1:CD003041.
18. Rigotti NA, McKool KM, Shiffman S. Predictors of smoking cessation after coronary artery bypass graft surgery. Results of a randomized trial with 5-year follow-up. Ann Intern Med 1994; 120:287-293.
19. Rigotti NA, Singer DE, Mulley AG Jr, et al. Smoking cessation following admission to a coronary care unit. J Gen Intern Med 1991; 6:305-311.
20. Fagerstrom K, Balfour DJ. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs 2006; 15:107-116.
21. Rose JE. Nicotine and nonnicotine factors in cigarette addiction. Psychopharmacology (Berl) 2006; 184:274-285.
22. McEwen A, Hayek P, McRobbie H, et al. Manual of smoking cessation: a guide for counsellors and practitioners. Oxford: Blackwell; 2006.
23. Frishman WH, Mitta W, Kupersmith A, et al. Nicotine and nonnicotine smoking cessation pharmacotherapies. Cardiol Rev 2006; 14:57-73.
24. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99:29-38.
25. Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence. Rockville: US Department of Health and Human Services, Public Health Service; 2000.
26. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; 3:CD000146.
27. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev 2005; 2:CD001292.
28. Ranney L, Melvin C, Lux L, et al. Systematic review: smoking cessation intervention strategies for adults and adults in special populations. Ann Intern Med 2006; 145:845-856.
29. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6:300.
30. Cahill K, Stead L, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; 1:CD006103. Systematic review and meta-analysis of clinical trial evidence of the efficacy and tolerability of nicotine partial agonists, including varenicline, for smoking cessation. From these data, varenicline increased the odds of quitting approximately three-fold compared with placebo. The number of people stopping smoking with varenicline was higher than with bupropion, with a lower risk of serious adverse effects.
31. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1:CD000031. Systematic review and meta-analysis of clinical trial evidence of the effect of antidepressant medication in aiding long-term smoking cessation. Trials of bupropion for smoking cessation indicate that it can approximately double the odds of quitting.
32. Vidrine JI, Cofta-Woerpel L, Daza P, et al. Smoking cessation 2: behavioral treatments. Behav Med 2006; 32:99-109.
33. Hurt RD. Treating tobacco dependence in a medical setting: best practices. In: Issacs SL, Schroeder SA, Simon JA, editors. VA in the vanguard: building on success in smoking cessation. Washington: VA Press; 2005. pp. 43-95.
34. Rigotti NA, Munafo MR, Murphy MF, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev 2003; 1:CD001837.
35. Barth J, Critchley J, Bengel J. Efficacy of psychosocial interventions for smoking cessation in patients with coronary heart disease: a systematic review and meta-analysis. Ann Behav Med 2006; 32:10-20. Systematic review and meta-analysis of clinical trial evidence of the efficacy of psychosocial interventions to quit smoking in patients with CHD. These trials showed that psychosocial interventions are effective in promoting abstinence up to 1 year, provided they are sufficient intensity with a minimum length of 1 month.
36. Wolfenden L, Campbell E, Walsh R, et al. Smoking cessation interventions for in-patients: a selective review with recommendations for hospital-based health professionals. Drug Alcohol Rev 2003; 22:437-452.
37. Foulds J, Steinberg MB, Williams JM, et al. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 2006; 25:59-71.
38. Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease. Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994; 154:989-995.
39. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996; 335:1792-1798.
40. Tzivoni D, Keren A, Meyler S, et al. Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking. Cardiovasc Drugs Ther 1998; 12:239-244.
41. Meine TJ, Patel MR, Washam JB, et al. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes. Am J Cardiol 2005; 95:976-978.
42. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 2004; 44:671-719.
43. Rigotti NA, Thorndike AN, Regan S, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med 2006; 119:1080-1087. First clinical trial showing that bupropion is safe for use among smokers hospitalized for acute cardiovascular disease. Bupropion increased short but not long-term cessation rates over 'best practice' smoking counseling.
44. Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166:1571-1577.
45. Nides M, Oncken C, Gonzales D, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166:1561-1568.
46. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296:56-63. One of the first two clinical trial reports of the efficacy of varenicline for smoking cessation.
47. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296:47-55. One of the first two clinical trial reports of the efficacy of varenicline for smoking cessation.
48. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296:64-71.
49. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006; 47:1919-1926.
50. Anthenelli RM. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US trial. American College of Cardiology Scientific Sessions. New Orleans, 2004.
51. Curry SJ, Orleans CT, Keller P, et al. Promoting smoking cessation in the healthcare environment: 10 years later. Am J Prev Med 2006; 31:269-272.
52. Orleans CT, Woolf SH, Rothemich SF, et al. The top priority: building a better system for tobacco-cessation counseling. Am J Prev Med 2006; 31:103-106.
53. Reid RD, Pipe AL, Quinlan B. Promoting smoking cessation during hospitalization for coronary artery disease. Can J Cardiol 2006; 22:775-780.